Cargando…

PKM2 enhances chemosensitivity to cisplatin through interaction with the mTOR pathway in cervical cancer

Pyruvate kinase M2 (PKM2) is a key driver of aerobic glycolysis in cancer cells and has been shown to be up-regulated by mTOR in vitro. Our previous proteomic profiling studies showed that PKM2 was significantly upregulated in cervical cancer tissues after treatment with neoadjuvant chemotherapy (NA...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Haiyan, Wu, Jun, Zhang, Wenwen, Luo, Hui, Shen, Zhaojun, Cheng, Huihui, Zhu, Xueqiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4974606/
https://www.ncbi.nlm.nih.gov/pubmed/27492148
http://dx.doi.org/10.1038/srep30788
_version_ 1782446573021560832
author Zhu, Haiyan
Wu, Jun
Zhang, Wenwen
Luo, Hui
Shen, Zhaojun
Cheng, Huihui
Zhu, Xueqiong
author_facet Zhu, Haiyan
Wu, Jun
Zhang, Wenwen
Luo, Hui
Shen, Zhaojun
Cheng, Huihui
Zhu, Xueqiong
author_sort Zhu, Haiyan
collection PubMed
description Pyruvate kinase M2 (PKM2) is a key driver of aerobic glycolysis in cancer cells and has been shown to be up-regulated by mTOR in vitro. Our previous proteomic profiling studies showed that PKM2 was significantly upregulated in cervical cancer tissues after treatment with neoadjuvant chemotherapy (NACT). Whether PKM2 expression predicts cisplatin-based NACT sensitivity and is mTOR dependent in cervical cancer patients remains unclear. Using paired tumor samples (pre- and post-chemotherapy) from 36 cervical cancer patients, we examined mTOR, HIF-1α, c-Myc, and PKM2 expression in cervical cancer samples and investigated the response to cisplatin-based NACT. In addition, we established PKM2 suppressed cervical cancer cell lines and evaluated their sensitivity to cisplatin in vitro. We found that the mTOR/HIF-1α/c-Myc/PKM2 signaling pathway was significantly downregulated in post-chemotherapy cervical cancer tissues. High levels of mTOR, HIF-1α, c-Myc, and PKM2 were associated with a positive chemotherapy response in cervical cancer patients treated with cisplatin-based NACT. In vitro, PKM2 knockdown desensitized cervical cancer cells to cisplatin. Moreover, PKM2 had complex interactions with mTOR pathways. mTOR, HIF1α, c-Myc, and PKM2 expression in cervical cancer may serve as predictive biomarkers to cisplatin-based chemotherapy. PKM2 enhances chemosensitivity to cisplatin through interaction with the mTOR pathway in cervical cancer.
format Online
Article
Text
id pubmed-4974606
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-49746062016-08-17 PKM2 enhances chemosensitivity to cisplatin through interaction with the mTOR pathway in cervical cancer Zhu, Haiyan Wu, Jun Zhang, Wenwen Luo, Hui Shen, Zhaojun Cheng, Huihui Zhu, Xueqiong Sci Rep Article Pyruvate kinase M2 (PKM2) is a key driver of aerobic glycolysis in cancer cells and has been shown to be up-regulated by mTOR in vitro. Our previous proteomic profiling studies showed that PKM2 was significantly upregulated in cervical cancer tissues after treatment with neoadjuvant chemotherapy (NACT). Whether PKM2 expression predicts cisplatin-based NACT sensitivity and is mTOR dependent in cervical cancer patients remains unclear. Using paired tumor samples (pre- and post-chemotherapy) from 36 cervical cancer patients, we examined mTOR, HIF-1α, c-Myc, and PKM2 expression in cervical cancer samples and investigated the response to cisplatin-based NACT. In addition, we established PKM2 suppressed cervical cancer cell lines and evaluated their sensitivity to cisplatin in vitro. We found that the mTOR/HIF-1α/c-Myc/PKM2 signaling pathway was significantly downregulated in post-chemotherapy cervical cancer tissues. High levels of mTOR, HIF-1α, c-Myc, and PKM2 were associated with a positive chemotherapy response in cervical cancer patients treated with cisplatin-based NACT. In vitro, PKM2 knockdown desensitized cervical cancer cells to cisplatin. Moreover, PKM2 had complex interactions with mTOR pathways. mTOR, HIF1α, c-Myc, and PKM2 expression in cervical cancer may serve as predictive biomarkers to cisplatin-based chemotherapy. PKM2 enhances chemosensitivity to cisplatin through interaction with the mTOR pathway in cervical cancer. Nature Publishing Group 2016-08-05 /pmc/articles/PMC4974606/ /pubmed/27492148 http://dx.doi.org/10.1038/srep30788 Text en Copyright © 2016, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Zhu, Haiyan
Wu, Jun
Zhang, Wenwen
Luo, Hui
Shen, Zhaojun
Cheng, Huihui
Zhu, Xueqiong
PKM2 enhances chemosensitivity to cisplatin through interaction with the mTOR pathway in cervical cancer
title PKM2 enhances chemosensitivity to cisplatin through interaction with the mTOR pathway in cervical cancer
title_full PKM2 enhances chemosensitivity to cisplatin through interaction with the mTOR pathway in cervical cancer
title_fullStr PKM2 enhances chemosensitivity to cisplatin through interaction with the mTOR pathway in cervical cancer
title_full_unstemmed PKM2 enhances chemosensitivity to cisplatin through interaction with the mTOR pathway in cervical cancer
title_short PKM2 enhances chemosensitivity to cisplatin through interaction with the mTOR pathway in cervical cancer
title_sort pkm2 enhances chemosensitivity to cisplatin through interaction with the mtor pathway in cervical cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4974606/
https://www.ncbi.nlm.nih.gov/pubmed/27492148
http://dx.doi.org/10.1038/srep30788
work_keys_str_mv AT zhuhaiyan pkm2enhanceschemosensitivitytocisplatinthroughinteractionwiththemtorpathwayincervicalcancer
AT wujun pkm2enhanceschemosensitivitytocisplatinthroughinteractionwiththemtorpathwayincervicalcancer
AT zhangwenwen pkm2enhanceschemosensitivitytocisplatinthroughinteractionwiththemtorpathwayincervicalcancer
AT luohui pkm2enhanceschemosensitivitytocisplatinthroughinteractionwiththemtorpathwayincervicalcancer
AT shenzhaojun pkm2enhanceschemosensitivitytocisplatinthroughinteractionwiththemtorpathwayincervicalcancer
AT chenghuihui pkm2enhanceschemosensitivitytocisplatinthroughinteractionwiththemtorpathwayincervicalcancer
AT zhuxueqiong pkm2enhanceschemosensitivitytocisplatinthroughinteractionwiththemtorpathwayincervicalcancer